Visgenx is a cutting-edge brand that is revolutionizing the field of retinal health and gene therapy. They are dedicated to developing innovative therapeutics based on increasing the expression of the ELOVL2 gene, which has been shown to regulate aging in the retina and other tissues. One of Visgenx's lead programs focuses on ELOVL2 gene therapy for Dry Age-Related Macular Degeneration (AMD), a progressive disease that results in the loss of photoreceptor cells and visual acuity.

This condition severely impacts everyday activities such as driving, cooking, reading, and facial recognition, affecting approximately 11 million people in the US. Visgenx's revolutionary approach targets the dysregulation of lipid (fatty acid) biosynthesis resulting from declining expression of the ELOVL2 gene underlying Dry Macular Degeneration. By turning back the clock and restoring a more youthful level of ELOVL2 expression, Visgenx aims to slow or halt aging-related disorders associated with the retina.

Backed by a team of expert scientists, entrepreneurs, and drug developers, Visgenx is at the forefront of scientific innovation in the field. Their ultimate goal is to develop therapeutics that combat cellular senescence in macular degeneration and other age-related disorders, ultimately improving the lives of countless individuals. To learn more about Visgenx and their groundbreaking work, visit their website and connect with them today